- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02230176
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM)
July 20, 2018 updated by: Gustave Roussy, Cancer Campus, Grand Paris
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II.
This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well differentiated pancreatic neuroendocrine tumors (WDpNET).
Subjects must have experienced documented progression of disease within 1 year prior to the start of the study.
The control group of patients receiving Sutent will be used as internal control to assess the hypothesis of 12 months PFS equal to 35% in patients receiving Sutent.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Eric BAUDIN, MD, PhD
- Phone Number: +33 0142114244
- Email: eric.baudin@gustaveroussy.fr
Study Contact Backup
- Name: Agnès LAPLANCHE, MD
- Phone Number: +33 0142114127
- Email: agnes.laplanche@gustaveroussy.fr
Study Locations
-
-
Val De Marne
-
Villejuif, Val De Marne, France, 94805
- Recruiting
- Gustave Roussy
-
Contact:
- Lisa LAMBERT
- Phone Number: +33 0142116643
- Email: lisa.lambert@gustaveroussy.fr
-
Principal Investigator:
- Eric BAUDIN, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically proven and reviewed well differentiated malignant pancreatic sporadic NET Metastatic disease not amenable to surgical resection
- All target lesions (lesions measurable and non-measurable according to the RECIST 1.1 criteria), of a size ≥ 15 mm, twice the spatial resolution of the somatostatin receptor scintigraphy (SRS), should be positive (grade of uptake at SRS≥ 2, equal to the physiologic liver uptake) within 24 weeks prior to enrollement. Negative target lesions are acceptable if below 15mm.
- Post first line whatever the type of systemic therapy: cytotoxic chemotherapy or everolimus or somatostatine analogs… Only one line of cytotoxic chemotherapy is authorized.
- Evaluable disease according to RECIST 1.1 criteria (Appendix 2)
- Progressing disease within 12 months prior to randomization according to RECIST 1.1 criteria ;
- ECOG performance status 0-2 (appendix 9)
- Life expectancy ≥ 6 months as prognosticated by the physician
- Age ≥ 18 years, no superior limit
- Adequate bone marrow reserve (Hb > 8, neutrophils ≥ 1500/mm³ and platelets ≥80.000/mm^3)
- Effective contraception in pre-menopausal female and male patients during and for at least 6 months post-treatment.
- Patient´s signed written informed consent
- Ability to comply with the protocol procedures
- Ability to take oral medication
- Patient affiliated to a social security system or beneficiary of the same.
Exclusion Criteria:
- Large or small cell-poorly differentiated pancreatic neuroendocrine tumor according to WHO 2010 classification
- Any patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of 177Lu-DOTA0-Tyr3-Octreotate, or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of 177Lu-DOTA0-Tyr3-Octreotate, unless OctreoScan® imaging during continued Octreotide treatment is in accordance with the inclusion criteria n°2.
- More than one line of cytotoxic chemotherapy (a patient who received the same molecules of cytotoxic chemotherapy at several times during therapeutic management is considered to have benefit from one single line of cytotoxic chemotherapy)
- Prior external beam radiation therapy to more than 25% of the bone marrow
- Urinary incontinence
- History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least five years.
- Severe renal (measured GFR according to MDRD <50ml/mn or nephrotic syndrome) or hepatic insufficiency (ALT / AST > 2.5 x ULN or ALT/AST >5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin > 2.5 x ULN)
- Serum albumin <3.0 g/dL unless prothrombin time is within the normal range.
- Uncontrolled diabetes mellitus as defined by a fasting blood glucose above 2 ULN
- Decompensated heart failure (ejection fraction <45%), myocardial infarction, stroke, pulmonary embolism or revascularization procedure,unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant bradycardia during the last 12 months.
- Hypertension that cannot be controlled despite medications (>=160/95 mmHg despite optimal medical therapy)
- Abnormal cardiac function with 12 lead ECG. Ongoing cardiac dysrhythmias of NCI CTC grade 2, atrial fibrillation of any grade, or prolongation of the QTc interval to >470 msec for males or >480 msec for females.
- Brain metastases (unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrolment in the study. Patients with a history of brain metastases must have a head CTscan with contrast or MRI to document stable disease prior to enrolment in the study.)
- Pregnancy or breast feeding (see appendix 6)
- Previous treatment with the drugs under study. Prior systemic treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors.
- Current treatment with another investigational drug.
- Treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days, respectively prior to study drug administration.
- Prior treatments with chemotherapy or immunotherapy or somatostatine analog therapy drug (except in case of functioning syndrome for somatostatine analogue therapy) or thoracic radiotherapy within 4 weeks prior to start of treatment
- Major surgery for any cause or local radiotherapy within one month prior to start of treatment
- Liver embolisation therapy within the last 3 months prior start of treatment except if progression is demonstrated and embolised lesion not used as targets
- Unrecovered toxicity from any kind of therapy
- Active or suspected acute or chronic uncontrolled disease that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration,or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 177Lu-DOTA0-Tyr3-Octreotate or OCLU
7.4 GBq per injection (max: 4 injections)
|
|
Active Comparator: Sunitinib
37.5 mg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the 12 months PFS
Time Frame: Assessed 12 months after randomization
|
Assessed 12 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Assessed every 3 months until death
|
Assessed every 3 months until death
|
|
Best response
Time Frame: Assessed every 12 weeks until progression up to 48 months
|
According to RECIST V1.1
|
Assessed every 12 weeks until progression up to 48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Eric BAUDIN, MD, Gustave Roussy, Cancer Campus, Grand Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
August 27, 2014
First Submitted That Met QC Criteria
August 29, 2014
First Posted (Estimate)
September 3, 2014
Study Record Updates
Last Update Posted (Actual)
July 23, 2018
Last Update Submitted That Met QC Criteria
July 20, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Pancreatic Diseases
- Neuroendocrine Tumors
- Pancreatic Neoplasms
- Carcinoma, Neuroendocrine
- Carcinoma, Islet Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Radiopharmaceuticals
- Protein Kinase Inhibitors
- Sunitinib
- Lutetium Lu 177 dotatate
Other Study ID Numbers
- 2013-004032-30
- 2013/2043 (Other Identifier: CSET number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Neuroendocrine Carcinoma
-
Roswell Park Cancer InstituteIpsenActive, not recruitingUnresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditionsUnited States
-
University of Michigan Rogel Cancer CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2United States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingMetastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingGastric Neuroendocrine Carcinoma | Intestinal Neuroendocrine Carcinoma | Pancreatic Neuroendocrine CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedLocally Advanced Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Pancreatic Vipoma | Pancreatic Gastrinoma | Advanced Pancreatic Neuroendocrine TumorUnited States, Canada
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Peking UniversityUnknownEsophageal Neuroendocrine Carcinoma | Gastro-entero-pancreatic CarcinomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Pancreatic Neuroendocrine CarcinomaUnited States
-
Grupo Espanol de Tumores NeuroendocrinosCompleted
Clinical Trials on Sunitinib
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletedPlatinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian TubeGermany
-
Mothaffar RimawiTerminated
-
Cogent Biosciences, Inc.RecruitingMetastatic Cancer | Advanced Gastrointestinal Stromal TumorsUnited States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
PfizerCompletedBreast NeoplasmsUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompleted
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Asan Medical CenterCompletedMetastatic Renal Cell CarcinomaKorea, Republic of